--- title: "DoctorDerm 推出品牌重塑，并扩展平台，新增处方皮肤和睫毛治疗" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/286923716.md" description: "DoctorDerm 宣布进行全面的品牌重塑，并扩展其远程皮肤科平台，推出新的处方治疗方案。此次品牌重塑强调简单和个性化护理，摒弃一刀切的解决方案。新产品包括用于改善皮肤质量的铜肽皮肤复合物和用于增强睫毛外观的睫毛生长精华。这两种治疗方案在经过持证提供者的评估后可在全国范围内提供，体现了 DoctorDerm 对于可及性和临床指导护肤的承诺" datetime: "2026-05-19T13:40:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286923716.md) - [en](https://longbridge.com/en/news/286923716.md) - [zh-HK](https://longbridge.com/zh-HK/news/286923716.md) --- # DoctorDerm 推出品牌重塑，并扩展平台，新增处方皮肤和睫毛治疗 SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- DoctorDerm today announced a comprehensive rebrand alongside the expansion of its personalized telehealth dermatology platform, introducing new prescription treatments designed to further its mission of making clinically guided skincare more accessible. The rebrand reflects a sharpened focus on simplicity, personalization, and provider-led care, making prescription dermatology a more seamless, accessible online experience. At the core of DoctorDerm is a model built around licensed providers who create customized treatment plans tailored to individual needs. By combining medical expertise with a streamlined online platform, DoctorDerm continues to move away from one-size-fits-all skincare toward more precise, personalized care. As part of this next phase, DoctorDerm is introducing two new prescription offerings: The Copper Peptide Skin Complex is a compounded topical formulation featuring GHK-Cu Acetate, a bioactive peptide associated with collagen support and skin appearance and overall quality. The treatment is designed to support skin firmness, texture, and overall quality while reinforcing the skin barrier. The Lash Growth Serum combines Bimatoprost 0.05% and Latanoprost 0.003%, two clinically recognized prostaglandin analogs used to support longer, fuller, and darker lashes over time. Both treatments are available nationwide following evaluation by a licensed provider and reflect DoctorDerm's continued investment in expanding its prescription offerings across skin and hair-related concerns. The rebrand and product expansion mark a broader evolution for DoctorDerm as it continues to scale a more accessible, clinically grounded approach to skincare that is centered on personalization, consistency, and long-term results. **About DoctorDerm** DoctorDerm is a telehealth skincare platform delivering personalized, prescription-grade dermatologic care. Through licensed providers and customized formulations, DoctorDerm helps patients address a range of skin and hair concerns with clinically guided treatments designed for long-term goals—without the barriers of traditional in-office visits. Disclaimer: "Treatments may include compounded prescription medications that are not FDA-approved. These medications are prescribed following evaluation by a licensed provider. Individual results may vary." **Media Contact:** Jamie Neider 801.520.5785 414880@email4pr.com View original content to download multimedia:https://www.prnewswire.com/news-releases/doctorderm-unveils-rebrand-and-expands-platform-with-new-prescription-skin-and-lash-treatments-302776224.html SOURCE DoctorDerm ### 相关股票 - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md) ## 相关资讯与研究 - [“搞钱”，才是 Revolution 千亿神话密码](https://longbridge.com/zh-CN/news/286888792.md) - [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md) - [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md) - [BioMarin ENPP1 缺乏症三期临床试验折戟，BMN 401 未达临床获益终点](https://longbridge.com/zh-CN/news/286795745.md) - [XORTX 获战略投资](https://longbridge.com/zh-CN/news/286767527.md)